查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1942570

Clinical Oncology Next Generation Sequencing Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，临床肿瘤学次世代定序市场发展迅速，预计将从2025年的5.8亿美元增长到2026年的6.6亿美元，复合年增长率达13.3%。过去几年的成长可归因于癌症基因组研究的扩展、定序平台的普及、肿瘤临床试验的增加、分子诊断的日益普及以及定序成本的下降。

预计未来几年，临床肿瘤学次世代定序市场将快速成长，到2030年市场规模将达到10.4亿美元，复合年增长率（CAGR）为12.1%。预测期内的成长要素包括：精准肿瘤学需求的不断增长、基因组医学投资的增加、院内定序检查室的扩建、标靶癌症治疗方法的日益普及以及定序技术的持续进步。预测期内的关键趋势包括：基于NGS的肿瘤诊断方法的日益普及、伴随诊断应用的广泛应用、生物资讯学和数据分析的日益融合、个人化癌症治疗方法的扩展以及对罕见突变检测的日益重视。

癌症发生率的上升预计将推动临床肿瘤学次世代定序（NGS）市场的成长。癌症是指一组疾病，其特征是异常细胞在体内不受控制地生长和扩散。 NGS在检测癌症中的新型和罕见突变方面发挥关键作用，有助于更好地了解个别肿瘤的分子基础。例如，根据美国政府机构国家癌症研究所2024年5月发布的报告，美国约有1810万名癌症倖存者。预计到2032年，这一数字将增加至2,250万。到2040年，预计每年新增癌症病例将达2,990万例，癌症相关死亡人数预计将增加至1,530万人。因此，癌症发生率的上升是推动临床肿瘤学次世代定序市场扩张的主要因素。

在临床肿瘤学次世代定序(NGS) 市场中，主要企业正着力推动技术进步。这包括整合软体加速器，从而显着降低二次 NGS 分析所需的时间和成本，使实验室能够更快地产生结果，同时减少运算资源需求。这些加速器解决方案能够实现全面的基因组分析，并提高大规模集中式实验室和分散式诊断环境中高通量癌症基因panel的可及性。例如，2024年1月，总部位于德国的生物资讯公司QIAGEN Digital Insights宣布对其CLC Genomics Workbench Premium进行升级，整合LightSpeed技术以支援体细胞癌的二次分析。 LightSpeed加速器可在标准云环境下，以低于0.72美元/次的成本，在约6分钟内处理一个覆盖度为3377倍的275基因癌症基因panel。 LightSpeed旨在以低功耗提供高性能和高精度，无需在现有CLC平台之外购买新的硬体或额外许可证。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 世界の临床オンコロジー次世代定序市场：魅力度スコアと分析
  • 成长潜力分析、竞争评估、策略契合度评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 主要原料、资源和供应商清单
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章 全球市场趋势与策略

  • 关键技术和未来趋势
    • 生物技术、基因组学和精准医学
    • 人工智慧（AI）和自主人工智慧
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 物联网、智慧基础设施和互联生态系统
  • 主要趋势
    • 次世代定序（NGS）ベースの肿疡诊断の采用拡大
    • 伴随诊断应用程式的广泛应用
    • 生物资讯与数据分析整合的进展
    • 拓展个人化癌症治疗方法
    • 人们越来越关注罕见突变检测

第五章 终端用户产业市场分析

  • 医院检查室
  • 临床研究所
  • 诊断检查室
  • 癌症研究所
  • 学术医疗中心

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及新冠疫情对市场的影响

第七章 全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球临床肿瘤学次世代定序市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 世界の临床オンコロジー次世代定序市场规模、比较、成长率分析
  • 全球临床肿瘤学次世代定序市场表现：规模与成长，2020-2025年
  • 世界の临床オンコロジー次世代定序市场の予测：规模と成长, 2025-2030, 2035F

第八章 全球潜在市场规模（TAM）

第九章 市场细分

  • 透过技术
  • イオン半导体シーケン定序、焦磷酸测序、合成シーケン定序、リアルタイムシーケン定序、リガースィーケン定序、可逆性色素终止シーケン定序、ナノポアシーケン定序
  • 透过使用
  • 筛检、伴随诊断和其他诊断
  • 最终用户
  • 病院ラボ、临床研究机関、诊断ラボ
  • 按类型细分：离子半导体定序
  • Ion Proton 系统、Ion PGM 系统、Ion S5 系统以及其他 Ion 半导体定序技术
  • 依类型进行亚片段化：焦磷酸测序
  • 454焦磷酸测序、その他の焦磷酸测序技术
  • 按类型细分：合成序列
  • イルミナ・シーケン定序技术、SOLiDシーケン定序技术、その他の合成シーケン定序技术
  • 按类型细分：即时定序
  • PacBio RS II 系统、Sequel 系统和其他即时定序技术
  • 按类型进行亚片段化：接合性定序
  • Helicos单分子定序和其他连接定序技术
  • 按类型进行亚分割：可逆染料终止定序
  • Illumina HiSeq、Illumina NextSeq 和其他可逆染料终止定序技术
  • 按类型细分：奈米孔定序
  • オックスフォードナノポアテクノロジーズ（MinION、GridION、PromethION）、その他のナノポアシーケン定序技术

第十章 区域与国家分析

  • 全球临床肿瘤学次世代定序市场：按地区、绩效和预测划分，2020-2025年、2025-2030年预测、2035年预测
  • 全球临床肿瘤学次世代定序市场：国家/地区、绩效及预测，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章 印度市场

第十四章 日本市场

第十五章：澳洲市场

第十六章 印尼市场

第十七章 韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第二十章：西欧市场

第21章英国市场

第22章 德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章 东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第30章：加拿大市场

第31章 南美洲市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第35章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 临床オンコロジー次世代定序市场：竞合情势と市场シェア、2024年
  • 临床肿瘤学次世代定序市场：公司估值矩阵
  • 临床肿瘤学次世代定序市场：公司概况
    • Thermo Fisher Scientific
    • Oxford Nanopore Technologies Ltd.
    • QIAGEN NV
    • Myriad Genetics Inc.
    • Illumina Inc.

第37章：其他领先和创新企业

  • F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company（BD）, Takara Bio Inc.

第38章 全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 临床オンコロジー次世代定序市场2030：新たな机会を提供する国
  • 临床オンコロジー次世代定序市场2030：新たな机会を提供するセグメント
  • 临床オンコロジー次世代定序市场2030：成长戦略
    • 基于市场趋势的策略
    • 竞争对手策略

第41章附录

简介目录
Product Code: ME5MCONG01_G26Q1

Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.

The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.

Tariffs are impacting the clinical oncology next generation sequencing market by increasing costs of imported sequencing instruments, reagents, flow cells, chips, and advanced bioinformatics hardware. Hospital laboratories and research institutions in North America and Europe are most affected due to reliance on imported sequencing platforms, while Asia-Pacific faces cost pressure on instrument manufacturing and reagent supply. These tariffs are raising operational costs and slowing technology upgrades. However, they are also encouraging regional production of sequencing consumables, domestic instrument assembly, and development of localized genomic analysis solutions.

The clinical oncology next generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next generation sequencing market statistics, including clinical oncology next generation sequencing industry global market size, regional shares, competitors with a clinical oncology next generation sequencing market share, detailed clinical oncology next generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next generation sequencing industry. This clinical oncology next generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.58 billion in 2025 to $0.66 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to expansion of cancer genomics research, increased availability of sequencing platforms, growth in oncology clinical trials, rising adoption of molecular diagnostics, declining sequencing costs.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $1.04 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for precision oncology, rising investments in genomic medicine, expansion of hospital-based sequencing laboratories, growing use of targeted cancer therapies, continuous advancements in sequencing technologies. Major trends in the forecast period include increasing adoption of ngs-based oncology diagnostics, rising use of companion diagnostic applications, growing integration of bioinformatics and data analytics, expansion of personalized cancer treatment approaches, enhanced focus on rare mutation detection.

The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.

Major companies operating in the clinical oncology next-generation sequencing (NGS) market are emphasizing technological advancements, including the integration of software accelerators that significantly cut the time and cost associated with secondary NGS analysis, allowing laboratories to generate results more rapidly while reducing computational resource requirements. These accelerator solutions enable comprehensive genomic profiling and improve the accessibility of high-throughput cancer panels for both large centralized laboratories and decentralized diagnostic environments. For instance, in January 2024, QIAGEN Digital Insights, a Germany-based bioinformatics company, introduced an upgraded version of its CLC Genomics Workbench Premium incorporating LightSpeed technology with support for somatic cancer secondary analysis. The LightSpeed accelerator is capable of processing a 275-gene cancer panel at 3377X coverage in approximately six minutes, at a cost of less than US$0.72 per test in standard cloud settings. LightSpeed is designed to deliver high performance and accuracy with lower power consumption and does not require new hardware or additional licenses beyond the existing CLC platform.

In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.

Major companies operating in the clinical oncology next generation sequencing market are Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

North America was the largest region in the clinical oncology next-generation sequencing market in 2025. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Oncology Next Generation Sequencing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical oncology next generation sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clinical oncology next generation sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
  • 2) By Application: Screening; Companion Diagnostics; Other Diagnostics
  • 3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic Laboratories
  • Subsegments:
  • 1) By Ion Semiconductor Sequencing: Ion Proton System; Ion PGM System; Ion S5 System; Other Ion Semiconductor Sequencing Technologies
  • 2) By Pyro-Sequencing: 454 Pyrosequencing; Other Pyro-Sequencing Technologies
  • 3) By Synthesis Sequencing: Illumina Sequencing Technology; SOLiD Sequencing Technology; Other Synthesis Sequencing Technologies
  • 4) By Real-Time Sequencing: PacBio RS II System; Sequel System; Other Real-Time Sequencing Technologies
  • 5) By Ligation Sequencing: Helicos Single Molecule Sequencing; Other Ligation Sequencing Technologies
  • 6) By Reversible Dye Termination Sequencing: Illumina HiSeq; Illumina NextSeq; Other Reversible Dye Termination Sequencing Technologies
  • 7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION); Other Nano-Pore Sequencing Technologies
  • Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.; F. Hoffmann-La Roche Ltd.; PerkinElmer Inc.; Agilent Technologies Inc.; Pacific Biosciences of California Inc.; Caris Life Sciences; Paradigm Diagnostics; GATC Biotech AG; Macrogen Inc.; DNASTAR Inc.; Exosome Diagnostics Inc.; Biomatters Ltd.; Partek Inc.; Foundation Medicine Inc.; Becton Dickinson and Company (BD); Takara Bio Inc.; Knome Inc.; Genomatix Software GmbH; CLC bio; GnuBIO Inc.; Bio-Rad Laboratories Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Sysmex Corporation; Veracyte Inc.; Zymo Research Corporation; ArcherDX Inc.; Karius Inc.; OncoDNA S.A.; Personal Genome Diagnostics Inc.; PierianDx Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Clinical Oncology Next Generation Sequencing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Clinical Oncology Next Generation Sequencing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Clinical Oncology Next Generation Sequencing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Clinical Oncology Next Generation Sequencing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Ngs-Based Oncology Diagnostics
    • 4.2.2 Rising Use Of Companion Diagnostic Applications
    • 4.2.3 Growing Integration Of Bioinformatics And Data Analytics
    • 4.2.4 Expansion Of Personalized Cancer Treatment Approaches
    • 4.2.5 Enhanced Focus On Rare Mutation Detection

5. Clinical Oncology Next Generation Sequencing Market Analysis Of End Use Industries

  • 5.1 Hospital Laboratories
  • 5.2 Clinical Research Organizations
  • 5.3 Diagnostic Laboratories
  • 5.4 Cancer Research Institutes
  • 5.5 Academic Medical Centers

6. Clinical Oncology Next Generation Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Clinical Oncology Next Generation Sequencing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Clinical Oncology Next Generation Sequencing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Clinical Oncology Next Generation Sequencing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Clinical Oncology Next Generation Sequencing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Clinical Oncology Next Generation Sequencing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Clinical Oncology Next Generation Sequencing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Clinical Oncology Next Generation Sequencing Market Segmentation

  • 9.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
  • 9.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Screening, Companion Diagnostics, Other Diagnostics
  • 9.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories
  • 9.4. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ion Semiconductor Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies
  • 9.5. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Pyro-Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 454 Pyrosequencing, Other Pyro-Sequencing Technologies
  • 9.6. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Synthesis Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies
  • 9.7. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Real Time Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies
  • 9.8. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ligation Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies
  • 9.9. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Reversible Dye Termination Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies
  • 9.10. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Nano-Pore Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

10. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis

  • 10.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Clinical Oncology Next Generation Sequencing Market

  • 11.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Clinical Oncology Next Generation Sequencing Market

  • 12.1. China Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Clinical Oncology Next Generation Sequencing Market

  • 13.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Clinical Oncology Next Generation Sequencing Market

  • 14.1. Japan Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Clinical Oncology Next Generation Sequencing Market

  • 15.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Clinical Oncology Next Generation Sequencing Market

  • 16.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Clinical Oncology Next Generation Sequencing Market

  • 17.1. South Korea Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Clinical Oncology Next Generation Sequencing Market

  • 18.1. Taiwan Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Clinical Oncology Next Generation Sequencing Market

  • 19.1. South East Asia Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Clinical Oncology Next Generation Sequencing Market

  • 20.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Clinical Oncology Next Generation Sequencing Market

  • 21.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Clinical Oncology Next Generation Sequencing Market

  • 22.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Clinical Oncology Next Generation Sequencing Market

  • 23.1. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Clinical Oncology Next Generation Sequencing Market

  • 24.1. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Clinical Oncology Next Generation Sequencing Market

  • 25.1. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Clinical Oncology Next Generation Sequencing Market

  • 26.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Clinical Oncology Next Generation Sequencing Market

  • 27.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Clinical Oncology Next Generation Sequencing Market

  • 28.1. North America Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Clinical Oncology Next Generation Sequencing Market

  • 29.1. USA Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Clinical Oncology Next Generation Sequencing Market

  • 30.1. Canada Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Clinical Oncology Next Generation Sequencing Market

  • 31.1. South America Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Clinical Oncology Next Generation Sequencing Market

  • 32.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Clinical Oncology Next Generation Sequencing Market

  • 33.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Clinical Oncology Next Generation Sequencing Market

  • 34.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Clinical Oncology Next Generation Sequencing Market Regulatory and Investment Landscape

36. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles

  • 36.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Clinical Oncology Next Generation Sequencing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Clinical Oncology Next Generation Sequencing Market Company Profiles
    • 36.3.1. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Clinical Oncology Next Generation Sequencing Market Other Major And Innovative Companies

  • F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc.

38. Global Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

40. Clinical Oncology Next Generation Sequencing Market High Potential Countries, Segments and Strategies

  • 40.1 Clinical Oncology Next Generation Sequencing Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Clinical Oncology Next Generation Sequencing Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Clinical Oncology Next Generation Sequencing Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer